Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-12-30 00:00:00 ET · period of report 2022-12-28 · accession 0001883850-22-000143 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-12-30 | 2022-12-28 | REGN | COLES N ANTHONY | Dir | S - Sale+OE | $714.11 | -5,758 | 1,404 | -80% | -$4.11M |
| DM | 2022-12-30 | 2022-12-28 | REGN | COLES N ANTHONY | Dir | M - OptEx | $442.24 | +5,758 | 6,851 | +527% | +$2.55M |
| DM | 2022-12-30 | 2022-12-28 | REGN | COLES N ANTHONY | Dir | M - OptEx | $0.00 | -5,758 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-28 | S | D | 181 | $707.87 | 6,670 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-28 | M | A | 2,145 | $374.12 | 3,238 | D | — | — | |
| 3 | Common | Common Stock | 2022-12-28 | M | A | 3,613 | $482.68 | 6,851 | D | — | — | |
| 4 | Common | Common Stock | 2022-12-28 | S | D | 311 | $716.08 | 1,093 | D | — | — | (F6) Represents volume-weighted average price of sales of 311 shares of Company stock on December 28, 2022 at prices ranging from $716.02 to $716.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. |
| 5 | Common | Common Stock | 2022-12-28 | S | D | 1 | $709.92 | 6,669 | D | — | — | |
| 6 | Common | Common Stock | 2022-12-28 | S | D | 679 | $710.63 | 5,990 | D | — | — | (F2) Represents volume-weighted average price of sales of 679 shares of Company stock on December 28, 2022 at prices ranging from $710.48 to $710.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. |
| 7 | Common | Common Stock | 2022-12-28 | S | D | 100 | $711.95 | 5,890 | D | — | — | |
| 8 | Common | Common Stock | 2022-12-28 | S | D | 1,198 | $713.66 | 4,692 | D | — | — | (F3) Represents volume-weighted average price of sales of 1,198 shares of Company stock on December 28, 2022 at prices ranging from $713.17 to $713.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. |
| 9 | Common | Common Stock | 2022-12-28 | S | D | 1,022 | $714.61 | 3,670 | D | — | — | (F4) Represents volume-weighted average price of sales of 1,022 shares of Company stock on December 28, 2022 at prices ranging from $714.00 to $714.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. |
| 10 | Common | Common Stock | 2022-12-28 | S | D | 2,266 | $715.48 | 1,404 | D | — | — | (F5) Represents volume-weighted average price of sales of 2,266 shares of Company stock on December 28, 2022 at prices ranging from $715.04 to $715.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. |
| 11 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-12-28 | M | D | 3,613 | $0.00 | 0 | D | $482.68 · — to 2031-01-04 | 3,613 Common Stock | (F7) On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. |
| 12 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-12-28 | M | D | 2,145 | $0.00 | 0 | D | $374.12 · — to 2030-01-02 | 2,145 Common Stock | (F7) On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. |